Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

149.87 +3.64 (+2.49%)
Streaming Delayed Price Updated: 1:42 PM EST, Feb 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
70 71 Next >
News headline image
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development ↗
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. 
Via InvestorPlace
News headline image
NASDAQ:GILD is probably undervalued for the fundamentals it is displaying. ↗
Investors should take notice ofGILEAD SCIENCES INC (NASDAQ:GILD)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street ↗
There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock. 
Via The Motley Fool
News headline image
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
From Gilead Sciences, Inc.
Via Business Wire
News headline image
A Look Into Gilead Sciences Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today ↗
 
Via Benzinga
News headline image
Looking Into Gilead Sciences's Recent Short Interest ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today ↗
 
Via Benzinga
News headline image
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Is NASDAQ:GILD suited for dividend investing? ↗
Why the dividend investor may take a look at GILEAD SCIENCES INC (NASDAQ:GILD). 
Via Chartmill
News headline image
Gilead Sciences's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions ↗
Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion... 
Via Benzinga
News headline image
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
From Gilead Sciences, Inc.
Via Business Wire
News headline image
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks ↗
Regulators are already on the case, and their findings will have financial impacts. 
Via The Motley Fool
News headline image
3 biotech powerhouses poised to thrive amid sector rebound
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. 
Via MarketBeat
Topics ETFs
News headline image
A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene
Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
News headline image
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy ↗
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. 
Via InvestorPlace
News headline image
3 Biotech Stocks That Could Be Multibaggers in the Making ↗
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments. 
Via InvestorPlace
News headline image
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
From Gilead Sciences, Inc.
Via Business Wire
News headline image
2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off. 
Via The Motley Fool
News headline image
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies ↗
Tuesday, the FDA said it received reports of patients developing T-cell malig 
Via Benzinga
News headline image
J&J, Gilead, BMS: A look at undervalued dividend payers
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown 
Via MarketBeat
News headline image
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later ↗
There's no time like the present to buy these stocks. 
Via The Motley Fool
News headline image
Stocks Stall On November 21, 2023, As Systematic Flows Abate ↗
Stocks finished the day lower by roughly 20 bps, which is not a big deal, as rates fell somewhat and the dollar rallied 
Via Talk Markets
News headline image
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug ↗
FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative... 
Via Benzinga
News headline image
In a market where value is scarce, NASDAQ:GILD offers a refreshing opportunity with its solid fundamentals. ↗
GILEAD SCIENCES INC (NASDAQ:GILD): good value for what you're paying. 
Via Chartmill
News headline image
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead ↗
The companies will work together on treatments for multiple myeloma and lymphomas. 
Via Investor's Business Daily
News headline image
Kite and Arcellx Announce Expansion in Strategic Partnership
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
70 71 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.